1. Scrip
  2. >>Business

IPO Update: Values Slip As Four More Biopharma Firms Go Public In October

 
• By Mandy Jackson

There were four biopharma IPOs in October – Myovant, Ra, CRISPR and AzurRX – but only one was trading above its offering price by the end of the month, reflecting investor uncertainty about the industry.

Four therapeutics developers completed initial public offerings in the US in October, bringing this year’s total to 28 biopharmaceutical IPOs, but values and returns have slipped for the class of 2016 as biotechnology stocks in general continue their year-to-date slide.

Myovant Sciences Ltd., Ra Pharmaceuticals Inc., CRISPR Therapeutics AG and AzurRx BioPharma Inc. went public in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Finance Watch: MapLight’s Mega-Round Funds Exploration Of Its Cobenfy Competitor

 
• By Mandy Jackson

Private Company Edition: MapLight raised a $372.5m series D round to fund ongoing Phase II trials and investigation of additional indications for its M1/M4 muscarinic agonist. Also, Scrip spoke with Modi Ventures about its new fund.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By Joseph Haas

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

EU 15% Tariff Deal Still Leaves Questions For Pharma

 
• By Jessica Merrill

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By Kevin Grogan

Comes Days After PDUFA Pushback For GSK's Blenrep.

More from Scrip

EU 15% Tariff Deal Still Leaves Questions For Pharma

 
• By Jessica Merrill

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 
• By Andrew McConaghie

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By Kevin Grogan

Comes Days After PDUFA Pushback For GSK's Blenrep.